Drug profile · INN
oxyphenonium bromide
ANTRENYL
oxyphenonium bromide (ANTRENYL) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — oxyphenonium bromide
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
oxyphenonium bromide (ANTRENYL) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscarinic acetylcholine receptor M1 antagonist
Primary target: Muscarinic acetylcholine receptor M1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is oxyphenonium bromide?
oxyphenonium bromide (ANTRENYL) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for oxyphenonium bromide?
ANTRENYL is a marketed brand name for oxyphenonium bromide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of oxyphenonium bromide?
oxyphenonium bromide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.